Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 131)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2, Phase 3, Phase 1 |
|
33069-62-4 |
36314
|
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-Paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-Taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
|
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL (TN)
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
2 |
|
Letrozole |
Approved, Investigational |
Phase 3,Phase 2 |
|
112809-51-5 |
3902
|
Synonyms:
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
Bio-0057
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
|
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
Letoval
Letrozol
letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
LS-38788
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
Novartis Brand of Letrozole
NSC719345
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
|
|
3 |
|
Tamoxifen |
Approved |
Phase 3 |
|
10540-29-1 |
2733526
|
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
10540-29-1
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
cMAP_000044
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
Lopac0_001203
LS-393
MLS001332535
MLS001332536
MolPort-003-850-384
NCGC00024928-01
NCGC00024928-03
|
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
NSC727681
Oncomox
Pms-Tamoxifen
PMS-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
Spectrum5_001417
Spectrum5_002043
ST50511785
T5648_SIGMA
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
tamoxifen
Tamoxifen
Tamoxifen (INN)
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifen Citrate
Tamoxifene
Tamoxifène
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tocris-0999
Tomaxithen
TRANS FORM OF TAMOXIFEN
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
|
|
4 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
50-18-0, 6055-19-2 |
2907
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
|
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
5 |
|
Doxorubicin |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
23214-92-8 |
31703
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
adriblatina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
|
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin HCl
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
DOX-SL
EINECS 245-495-6
Farmablastina (hydrochloride salt)
FI 106
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
|
|
6 |
|
Trastuzumab |
Approved, Investigational |
Phase 3,Phase 2 |
|
180288-69-1 |
9903
|
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
Herceptin (TN)
Ig gamma-1 chain C region
|
RHUMAB HER2
trastuzumab
Trastuzumab
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
Trastuzumab (INN)
trastuzumab-dkst
|
|
7 |
|
Carboplatin |
Approved |
Phase 3,Phase 1,Phase 2 |
|
41575-94-4 |
10339178
38904
498142
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
8 |
|
Anastrozole |
Approved, Investigational |
Phase 3,Phase 2 |
|
120511-73-1 |
2187
|
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC1L1D49
AC-4234
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrazole
Anastrole
Anastrozol
anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
|
CHEMBL1399
CID2187
CPD000466301
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD1033
ZD-1033
Zeneca brand of anastrozole
Zeneca ZD 1033
ZINC00000941
|
|
9 |
|
Exemestane |
Approved, Investigational |
Phase 3,Phase 2 |
|
107868-30-4 |
60198
|
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC1L1SRB
AC1Q6AAZ
AC-2171
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
Exemestance
exemestane
|
Exemestane
EXEMESTANE
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
Fce 24304
FCE-24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
Nikidess
NSC713563
Pfizer brand of exemestane
PNU-155971
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
|
|
10 |
|
Zoledronic acid |
Approved |
Phase 3 |
|
118072-93-8 |
68740
|
Synonyms:
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
Aclasta
AKOS005145739
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42446
CGP 42'446
CGP 42446A
CGP-42446
CGP-42'446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
|
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
Novartis brand of zoledronic acid
NSC721517
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
Zol
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
|
|
11 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311
|
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
|
Citrate
Citretten
Citric acid
Citric Acid, Anhydrous
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
|
|
12 |
|
Doxil |
Approved June 1999 |
Phase 3,Phase 2,Phase 1 |
|
|
31703
|
Synonyms:
|
LipoDox
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
|
|
13 |
|
Albumin-Bound Paclitaxel |
|
Phase 2, Phase 3, Phase 1 |
|
|
|
14 |
|
Antimitotic Agents |
|
Phase 2, Phase 3, Phase 1 |
|
|
|
15 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 2, Phase 3, Phase 1 |
|
|
|
16 |
|
Antirheumatic Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
17 |
|
Immunosuppressive Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
18 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
19 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3,Phase 2 |
|
|
|
20 |
|
Aromatase Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
21 |
|
Bone Density Conservation Agents |
|
Phase 3 |
|
|
|
22 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
23 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
24 |
|
Estrogen Antagonists |
|
Phase 3,Phase 2 |
|
|
|
25 |
|
Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
26 |
|
Estrogens |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
27 |
|
Hormone Antagonists |
|
Phase 3,Phase 2 |
|
|
|
28 |
|
Hormones |
|
Phase 3,Phase 2 |
|
|
|
29 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 3,Phase 2 |
|
|
|
30 |
|
Selective Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
31 |
|
Steroid Synthesis Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
32 |
|
Alkylating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
33 |
|
Anti-Bacterial Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
34 |
|
Antibiotics, Antitubercular |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
35 |
|
Topoisomerase Inhibitors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
36 |
|
Diphosphonates |
|
Phase 3 |
|
|
|
37 |
|
Citrate |
Nutraceutical |
Phase 3 |
|
|
|
38 |
|
Hydroxychloroquine |
Approved |
Phase 2 |
|
118-42-3 |
3652
|
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
EINECS 204-249-8
Gen-Hydroxychloroquine 200mg Tablets
HCQ
Hidroxicloroquina
Hidroxicloroquina [INN-Spanish]
HMS502P04
|
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
39 |
|
Lenograstim |
Approved, Investigational |
Phase 2,Phase 1 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
40 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2,Phase 1 |
|
22916-47-8 |
4189
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
|
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
41 |
|
Sulindac |
Approved, Investigational |
Phase 2 |
|
38194-50-2 |
1548887
5352
|
Synonyms:
(E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
[(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid
{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
32004-68-5
38194-50-2
53933-60-1
5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
6301-55-9
9000-14-0
AB00513800
AC1L1K5T
AC1LU7GU
AC1LU7GY
AC1Q6YHK
AC-4550
Aclin
Aflodac
AKOS004119989
Alphapharm Brand of Sulindac
Apo Sulin
Apo-Sulin
Apotex Brand of Sulindac
AR-1A9609
Arthrobid
Arthrocine
BB_SC-1128
BPBio1_000315
BRD-A03427350-001-01-3
BRD-A13946108-001-04-9
BRN 2951842
BSPBio_000285
BSPBio_002890
C01531
C20H17FO3S
Cahill May Roberts Brand of Sulindac
CAS-38194-50-2
CCRIS 3305
CHEBI:9352
CHEMBL1376
Chemia Brand of Sulindac
Chibret
CID1548885
CID1548887
CID5352
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
Clinoril
Clinoril (TN)
cMAP_000021
Copal
Copal resin
Copal rosin varnish
Copals
CPD000326718
D00120
D013467
DB00605
DivK1c_000601
EINECS 232-527-9
EINECS 250-893-8
EINECS 253-819-2
EINECS 258-873-0
EU-0101070
Gum copal
HMS1568O07
HMS1921C11
HMS2089J04
HMS2092K15
HMS501O03
I06-0523
IDI1_000601
KBio1_000601
KBio2_001506
KBio2_002320
|
KBio2_004074
KBio2_004888
KBio2_006642
KBio2_007456
KBio3_002110
KBio3_002800
KBioGR_001571
KBioGR_002320
KBioSS_001506
KBioSS_002322
Kenalin
Kendrick Brand of Sulindac
Klinoril
KST-1B6530
Lopac0_001070
Lopac-S-8139
LS-81610
Merck Brand of Sulindac
Merck Sharp & Dohme Brand of Sulindac
MK 231
MK231
MK-231
MLS001056554
MLS001304027
MLS002207124
Mobilin
MolPort-002-507-760
MolPort-003-666-287
NCGC00015970-01
NCGC00015970-02
NCGC00015970-03
NCGC00015970-08
NCGC00025268-01
NCGC00025268-02
NCGC00025268-03
NCGC00094349-01
NCGC00094349-02
NINDS_000601
Novo Sundac
Novopharm Brand of Sulindac
Novo-Sundac
Nu Pharm Brand of Sulindac
Nu Sulindac
Nu-Pharm Brand of Sulindac
Nu-Sulindac
Prestwick_456
Prestwick0_000073
Prestwick1_000073
Prestwick2_000073
Prestwick3_000073
Resin copal
S 8139
S2007_Selleck
S4429_SIAL
S8139_SIAL
S8139_SIGMA
SAM002554933
SBB058181
SMR000043852
SMR000326718
SPBio_001451
SPBio_002206
Spectrum_001026
SPECTRUM1500556
Spectrum2_001326
Spectrum3_001365
Spectrum4_000876
Spectrum5_001024
STK802068
sulindac
Sulindac
Sulindac (JAN/USP/INN)
Sulindac [USAN:BAN:INN:JAN]
Sulindac sulfoxide
Sulindaco
Sulindaco [INN-Spanish]
Sulindacum
Sulindacum [INN-Latin]
Sulindal
Tocris-1707
UNII-184SNS8VUH
UNII-M5221THD3M
UNM-0000306136
Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid
|
|
42 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4, 85898-30-2 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
43 |
|
Epirubicin |
Approved |
Phase 2 |
|
56420-45-2 |
41867
|
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epiadriamycin
4'-epidoxorubicin
4'-epi-Doxorubicin
4'-Epidoxorubicin
4-Epidoxorubicin
4'-epi-DX
4'-Epi-DXR
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epiadriamycin
Epidoxorubicin
Epi-Dx
Epi-DX
Epirubicin
Epirubicin (INN)
|
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC256942
NSC-256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
|
|
44 |
|
Testosterone |
Approved, Investigational |
Phase 2 |
|
58-22-0 |
6013
|
Synonyms:
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+)-testosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-hydroxy-4-androsten-3-one
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17-beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-hydroxy-4-androsten-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Testosterone
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-androst-4-en-3-one
17-Hydroxy-D4-androsten-3-one
46923_FLUKA
46923_RIEDEL
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-androsten-17β-ol-3-one
4-Androsten-3-one-17b-ol
4-androstene-17beta-ol-3-one
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
Androderm
Androderm (TN)
Androgel
AndroGel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17beta-ol-3-one
Androst-4-en-17b-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
beta testosterone
Beta Testosterone
BIDD:ER0555
BIM-0061761.0001
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-cristaux gremy
Geno-cristaux Gremy
Geno-Cristaux Gremy
Halotensin
HMS2052N11
|
Homosteron
Homosterone
HSDB 3398
Intrinsa
Libigel
LibiGel
LMST02020002
LS-148813
Lumitestosteron
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, aquaspension injection
Malogen, Aquaspension Injection
Mertestate
Metandren
Methyltestosterone
MLS000563091
MLS001032098
MLS001306401
MLS002174283
MolPort-002-506-901
NCGC00091018-01
Neo-Hombreol F
Neotestis
Neo-testis
Neo-Testis
NSC 9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine androgenique
Percutacrine Androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
Scheinpharm Testone-Cyp
SMR000058344
SMR001261453
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
testosterone
Testosterone
Testostérone
Testosterone (JAN/USP)
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone Cypionate
Testosterone Enanthate
Testosterone hydrate
Testosterone Hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron Schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro Aq
Testro AQ
Testrone
Testryl
Tostrelle
Tostrex
trans-Testosterone
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
|
|
45 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-28-2 |
5757
|
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17β)-estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
[2,4,6,7-3H]-E2
[3H]]estradiol
[3H]-estradiol
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17.beta.-Estradiol
17-.BETA.-Estradiol
17.beta.-Oestradiol
17b-Estradiol
17-beta
17beta oestradiol
17-beta-estradiol
17beta-Estradiol
17beta-Oestradiol
17-beta-OH-estradiol
17b-Oestradiol
17E
17-E
17β-estra-1,3,5(10)-triene-3,17-diol
17β-estradiol
17β-oestradiol
1jgl
1qkt
1qku
2d06
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17-Epidihydroxyestratriene
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
Bardiol
b-Estradiol
B-Estradiol
beta-Estradiol
Beta-estradiol
BIDD:ER0125
BIDD:PXR0065
Bio-0812
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
Bio-E-Gel
bmse000642
BPBio1_000532
BSPBio_000482
BSPBio_001065
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
cis-Estradiol
cis-Oestradiol
Climaderm
Climara
Climara (TN)
Climara Forte
cMAP_000005
CMC_11154
component of Menrium
Compudose
Compudose 200
Compudose 365
Corpagen
CPD000059126
CPD-352
D00105
D-3,17beta-Estradiol
DB00783
delta-Estradiol
delta-Oestradiol
Dermestril
Destradiol
D-Estradiol
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydro-Theelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
D-Oestradiol
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
estradiol
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17.beta.
estradiol-17beta
Estradiol-17beta
Estradiol-17-beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
|
Estreva
Estrifam
Estring
Estring (TN)
Estring vaginal ring
Estring Vaginal Ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
Estrogel (TN)
Estrogel HBF
Estrovite
EU-0100503
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
Gynergon
Gynestrel
Gynodiol
Gynoestryl
GynPolar
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
Lamdiol
LMST02010001
Lopac0_000503
LS-137
Macrodiol
Macrol
Menest
Menorest
Microdiol
MLS000069494
MLS000758312
MLS001076331
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
Nordicol
NSC9895
NSC-9895
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiol-17-beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick_207
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Primofol
Profoliol
Profoliol B
progynon
Progynon
Progynon DH
Progynon-DH
S1709_Selleck
S-21400
SAM001247032
Sandrena 1
Sandrena Gel
Sisare Gel
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
VIVELLE-DOT
Zerella
Zesteem
Zesteen
Zumenon
|
|
46 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
17756771
104741
|
Synonyms:
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC1L2XEN
AC-4693
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
|
Faslodex, ICI 182780, Fulvestrant
fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
Ici 182780
ICI-182780
LS-64781
NCGC00164789-02
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
|
|
47 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
5330286
11431660
5005498
|
Synonyms:
2euf
571190-30-2
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
Ibrance
|
Kinome_3823
Kinome_3824
LQQ
Palbociclib
PD 0332991
PD 332991, PD 0332991, PD0332991
PD0332991
PD-0332991
PD-332991
S1116_Selleck
|
|
48 |
|
Azacitidine |
Approved, Investigational |
Phase 2 |
|
320-67-2 |
9444
|
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AC
5AzaC
5-AZAC
5-azacitidine
5-aza-CR
5-azacytidine
5-Azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5-AZCR
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
cMAP_000082
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
|
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
Ladakamycin
Lopac0_000035
LS-1189
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
mylo sar
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC102816
NSC-102816
Pharmion Brand of Azacitidine
pyrimidine antimetabolite: inhibits nucleic acid replication
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
Spectrum_001262
SPECTRUM1502111
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
ST056940
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
wr 183027
WR-183027
ZINC03861768
|
|
49 |
|
Decitabine |
Approved, Investigational |
Phase 2 |
|
2353-33-5 |
451668
|
Synonyms:
2353-33-5
2'-Deoxy-5-azacytidine
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5A2dc
5-Aza-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-Aza-2'-deoxycytidine
5-aza-CdR
5-aza-dC
5-AZAdC
5-Azadeoxycytidine
5-Deoxy-2&prime
A3656_SIGMA
AC-1135
AC1L9PS9
-azacytidine
Azadc
AzadC
CHEBI:50131
|
CHEMBL1201129
CID451668
D03665
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
DB01262
Decitabine
Decitabine (USAN/INN)
-Deoxycytidine
Dezocitidine
E-7373
FT-0082622
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC127716
NSC-127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
|
|
50 |
|
Pembrolizumab |
Approved |
Phase 2,Phase 1,Early Phase 1 |
|
1374853-91-4 |
|
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 52)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer |
Completed |
NCT00949598
|
Phase 3 |
letrozole;tamoxifen citrate |
2 |
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer |
Recruiting |
NCT03337724
|
Phase 2, Phase 3 |
Ipatasertib;Paclitaxel;Placebo |
3 |
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
Recruiting |
NCT02488967
|
Phase 3 |
Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel |
4 |
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement |
Active, not recruiting |
NCT00869206
|
Phase 3 |
zoledronic acid |
5 |
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) |
Active, not recruiting |
NCT00310180
|
Phase 3 |
Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate |
6 |
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer |
Active, not recruiting |
NCT00005970
|
Phase 3 |
Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate |
7 |
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients |
Unknown status |
NCT01292408
|
Phase 2 |
Hydrochloroquine |
8 |
Study of MDX-010 in Stage IV Breast Cancer |
Completed |
NCT00083278
|
Phase 2 |
MDX-010 |
9 |
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer |
Completed |
NCT02063893
|
Phase 1, Phase 2 |
|
10 |
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer |
Completed |
NCT00039520
|
Phase 2 |
docetaxel;sulindac |
11 |
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer |
Completed |
NCT00019916
|
Phase 1, Phase 2 |
|
12 |
Chemotherapy in Treating Women With Metastatic Breast Cancer |
Completed |
NCT00004046
|
Phase 2 |
exatecan mesylate |
13 |
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer |
Completed |
NCT02301988
|
Phase 2 |
Ipatasertib;Paclitaxel;Placebo |
14 |
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes |
Completed |
NCT01693549
|
Phase 2 |
Cabazitaxel |
15 |
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer |
Completed |
NCT00054301
|
Phase 2 |
|
16 |
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility |
Completed |
NCT00591851
|
Phase 2 |
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) |
17 |
CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer |
Recruiting |
NCT02067741
|
Phase 2 |
CR1447 |
18 |
IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma |
Recruiting |
NCT02614833
|
Phase 2 |
Placebo;Paclitaxel |
19 |
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer |
Recruiting |
NCT01928589
|
Phase 1, Phase 2 |
|
20 |
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant |
Recruiting |
NCT02894398
|
Phase 2 |
Palbociclib;Letrozole;Anastrozole;Exemestane;Fulvestrant |
21 |
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread |
Recruiting |
NCT02322814
|
Phase 2 |
Cobimetinib;Paclitaxel;Placebo;Atezolizumab;Nab-Paclitaxel |
22 |
Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca |
Recruiting |
NCT02957968
|
Phase 2 |
Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab |
23 |
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer |
Recruiting |
NCT01697293
|
Phase 1, Phase 2 |
Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate |
24 |
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer |
Recruiting |
NCT01730833
|
Phase 2 |
paclitaxel albumin-stabilized nanoparticle formulation |
25 |
Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation |
Recruiting |
NCT01245712
|
Phase 2 |
|
26 |
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer |
Recruiting |
NCT02530489
|
Phase 2 |
MPDL3280A;Nab-paclitaxel |
27 |
Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation |
Active, not recruiting |
NCT02282345
|
Phase 2 |
Talazoparib |
28 |
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 |
Active, not recruiting |
NCT01593020
|
Phase 2 |
Paclitaxel;Eribulin;5-Fluorouracil;Epirubicin;Cyclophosphamide;Doxorubicin |
29 |
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer |
Suspended |
NCT03106415
|
Phase 1, Phase 2 |
Binimetinib |
30 |
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer |
Terminated |
NCT00074269
|
Phase 2 |
cyclosporine;fludarabine phosphate;melphalan;methotrexate |
31 |
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer |
Unknown status |
NCT00009763
|
Phase 1 |
cyclosporine;paclitaxel |
32 |
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast |
Completed |
NCT02204046
|
Phase 1 |
BIWA 4 |
33 |
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer |
Completed |
NCT00003761
|
Phase 1 |
|
34 |
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer |
Completed |
NCT01502592
|
Phase 1 |
|
35 |
Clinical Trial of Trametes Versicolor in Women With Breast Cancer |
Completed |
NCT00680667
|
Phase 1 |
|
36 |
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer |
Recruiting |
NCT02824575
|
Phase 1 |
Rebastinib;Paclitaxel;Eribulin Mesylate |
37 |
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) |
Recruiting |
NCT01724606
|
Phase 1 |
Sorafenib |
38 |
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer |
Recruiting |
NCT02453620
|
Phase 1 |
Entinostat |
39 |
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors |
Recruiting |
NCT03102320
|
Phase 1 |
Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343) |
40 |
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
Not yet recruiting |
NCT03432741
|
Phase 1 |
Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin |
41 |
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer |
Terminated |
NCT00071942
|
Phase 1 |
|
42 |
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas |
Unknown status |
NCT01942629
|
|
|
43 |
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility |
Completed |
NCT00617370
|
|
epirubicin, cyclophosphamide, Paclitaxel, |
44 |
Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer |
Completed |
NCT01024582
|
|
|
45 |
Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI |
Recruiting |
NCT02306538
|
|
|
46 |
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer |
Recruiting |
NCT03137693
|
|
|
47 |
Engineering Gut Microbiome to Target Breast Cancer |
Recruiting |
NCT03358511
|
|
|
48 |
Older Breast Cancer Patients: Risk for Cognitive Decline |
Recruiting |
NCT03451383
|
|
|
49 |
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer |
Recruiting |
NCT02515110
|
|
|
50 |
Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation |
Recruiting |
NCT03366844
|
Early Phase 1 |
Pembrolizumab |
|